Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG And Erbitux In Metastatic Colorectal Cancer Patients

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Biothera announced today that it has initiated enrollment of patients in a phase Ib/IIa clinical trial to evaluate the safety and efficacy of Imprime PGG(TM) and Erbitux(R) in patients with metastatic colorectal cancer.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.